JP2024531507A5 - - Google Patents
Info
- Publication number
- JP2024531507A5 JP2024531507A5 JP2024513347A JP2024513347A JP2024531507A5 JP 2024531507 A5 JP2024531507 A5 JP 2024531507A5 JP 2024513347 A JP2024513347 A JP 2024513347A JP 2024513347 A JP2024513347 A JP 2024513347A JP 2024531507 A5 JP2024531507 A5 JP 2024531507A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complement
- adenine
- creb3l3
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239304P | 2021-08-31 | 2021-08-31 | |
| US63/239,304 | 2021-08-31 | ||
| PCT/US2022/075610 WO2023034761A1 (en) | 2021-08-31 | 2022-08-29 | Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531507A JP2024531507A (ja) | 2024-08-29 |
| JP2024531507A5 true JP2024531507A5 (enExample) | 2025-06-09 |
Family
ID=83457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513347A Pending JP2024531507A (ja) | 2021-08-31 | 2022-08-29 | Ｃａｍｐ応答性エレメント結合タンパク質３様３（ｃｒｅｂ３ｌ３）阻害剤による肝疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230160012A1 (enExample) |
| EP (1) | EP4395888A1 (enExample) |
| JP (1) | JP2024531507A (enExample) |
| KR (1) | KR20240058125A (enExample) |
| CN (1) | CN118265529A (enExample) |
| AU (1) | AU2022339755A1 (enExample) |
| CA (1) | CA3228930A1 (enExample) |
| IL (1) | IL310697A (enExample) |
| WO (1) | WO2023034761A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR067446A1 (es) * | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| WO2012051301A1 (en) * | 2010-10-12 | 2012-04-19 | President And Fellows Of Harvard College | Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism |
| EP3220911B1 (en) * | 2014-11-17 | 2018-11-07 | Universitá Degli Studi Salerno | Levosimendan for use as a liver protector |
-
2022
- 2022-08-29 WO PCT/US2022/075610 patent/WO2023034761A1/en not_active Ceased
- 2022-08-29 AU AU2022339755A patent/AU2022339755A1/en active Pending
- 2022-08-29 JP JP2024513347A patent/JP2024531507A/ja active Pending
- 2022-08-29 CN CN202280067542.3A patent/CN118265529A/zh active Pending
- 2022-08-29 US US17/823,057 patent/US20230160012A1/en active Pending
- 2022-08-29 CA CA3228930A patent/CA3228930A1/en active Pending
- 2022-08-29 KR KR1020247010325A patent/KR20240058125A/ko active Pending
- 2022-08-29 IL IL310697A patent/IL310697A/en unknown
- 2022-08-29 EP EP22777885.9A patent/EP4395888A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study | |
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| US20230304088A1 (en) | Compositions and methods of detection of pre-symptomatic als | |
| JP2018088888A (ja) | Ｓｃｎ１ａ遺伝子の発現増強法 | |
| CN110295227B (zh) | 基于hsa-miR-320a的糖尿病早期预警和/或诊断试剂盒的制备方法 | |
| CN108004310B (zh) | 肾素(原)受体(p)rr基因及其抑制剂的应用 | |
| JP2024531507A5 (enExample) | ||
| JP2023539742A (ja) | Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 | |
| US20250188473A1 (en) | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | |
| CN110327363A (zh) | 基于hsa-miR-320a的防治糖尿病的药物及其筛选方法和制备方法 | |
| JP7575396B2 (ja) | 溶質キャリアファミリー３９メンバー５（ｓｌｃ３９ａ５）阻害剤を用いた高血糖の処置 | |
| Ghazalah et al. | Genetic study of I kappa B alpha gene promoter polymorphism associated with hepatitis C virus in Egyptian patients | |
| TW202327626A (zh) | 用於體內編輯肝臟基因之方法 | |
| JP2022525546A5 (enExample) | ||
| JP2024536491A5 (enExample) | ||
| Melkersson et al. | The insulin receptor substrate-4 (IRS-4) gene and schizophrenia: no evidence for a main genetic factor, however one report of a single schizophrenia patient with a mutation | |
| JP2024535110A5 (enExample) | ||
| US20250263699A1 (en) | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH siRNAS TARGETING TBX3 | |
| JP2024508824A5 (enExample) | ||
| JP2024533459A5 (enExample) | ||
| US20220387546A1 (en) | Methods For Treating And/Or Preventing Hypersomnias | |
| JP2024524554A5 (enExample) | ||
| CN121816419A (zh) | 用卵泡素相互作用蛋白1 (fnip1)抑制剂和/或卵泡素(flcn)抑制剂治疗肝病或代谢病症 | |
| CA3210481A1 (en) | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (gpam) inhibitors | |
| Lou et al. | Long-term therapeutic efficacy and safety profiles of hpCas13d RNA editing in treating early-onset hypertrophic cardiomyopathy |